Abstract: Objective To observe the clinical efficacy of cluster electrode radiofrequency ablation (RFA) combination with gefitinib for advanced lung adenocarcinoma.Methods Thirty-six patients with advanced lung adenocarcinoma of stage ⅢA and stage Ⅳ were treated with RFA and gefitinib combination therapy(referred to as the “treatment group”), while 33 patients were treated with only RFA(referred to as the “group”) as control. The efficacy, life quality and side effect of both groups were compared using χ² test.Results The response rate of combination therapy group was 66.7%(24/36), which is higher than that of RFA therapy group, with 30.3%(10/33) (χ²=9.07,P<0.05). There were 75.0%(24/36)patients of combination therapy group who had good quality of life, while in RFA therapy group, the proportion was 48.5%(16/33)(χ²=5.24,P<0.05). The side effects of patients were pain, diarrhea and fever.Conclusion The RFA and gefitinib combination therapy can improve the therapeutic efficacy in patients with advanced lung adenocarcinoma.